Lygature

We are proud to contribute to the CPBT (Centrum voor Proefdiervrije Biomedische Translatie). The new centre just launched its initial website. The CPBT aims to improve and accelerate the translation of new biomedical innovations to patients and users, with lower costs and without the use of animals. This will lead to safer, more effective, and better medicines while reducing animal testing. As a partner, Lygature provides program management and communication support to the CPBT, and will also contribute #regulatory expertise to the centre when it becomes fully operational. We are looking forward to working with the CPBT partners on the important mission of reducing animal testing. #biomedical #innovation #animalfree

Our Q3 Newsletter was recently released, providing a round-up of news from the past few months. In this edition, we cover developments in our projects related to #AntimicrobialResistance, #Tuberculosis, and #Cancer, among others. We also spotlight Lygature’s ongoing efforts in #DataSharing and #RegulatoryScience. Dive into these updates to learn more about our efforts to advance healthcare and foster impactful global collaborations 👉 https://lnkd.in/edhpCAjA #PublicPrivatePartnerships #PioneeringMedicineTogether #Newsletter

🌟Project launch 🌟 Lygature is pleased to partner in the recently launched Innovative Health Initiative (IHI) IHI ILLUMINATE project which aims to demonstrate the unique value of metabolic #MRIs to improve effective application of #theranostics in #prostate cancer while increasing availability of #lutetium for #cancer treatment. Lygature was instrumental in the set-up phase of the ILLUMINATE consortium. In close collaboration with UMC Utrecht, Lygature coordinated and supported the application process for the project, followed by the contractual negotiations between partners. Setting up the ILLUMINATE project required extensive expertise in science, and #partnership management. Within ILLUMINATE, Lygature provides program management and communication support, and contributes its #regulatory expertise. Learn more about ILLUMINATE via the Press Release (https://lnkd.in/eWtwvaWZ) and visit the website: https://lnkd.in/eVU-vk_k. Read the full news article here: https://lnkd.in/edVYY9Rx Cancer Research UMC Utrecht UMC Utrecht Euro-BioImaging, Philips, SYNLAB Italia, Consiglio Nazionale delle Ricerche, Università degli Studi di Torino, Bracco, Tesla Dynamic Coils, WaveTronica B.V., Lund University, NRG, Amsterdam UMC, University Hospital Essen.

Today is an important day for antimicrobial resistance (AMR) as the United Nations General Assembly meets to accelerate political action on AMR. As Coordinator of the GNA NOW Consortium, a project under the AMR Accelerator, our colleague Kristina Orrling contributed to a paper published this week in Nature Reviews Drug Discovery calling for sustainable investment in AMR Research & Development, as profiled here by the Innovative Health Initiative (IHI) 👇 Kristina notes: “Despite the high medical need, in AMR research the monetary incentives are low and the chance of return of investment infinitesimal. The only solution to this paradox is collaboration – I am utterly convinced that PPPs are necessary for bringing new antimicrobial drugs to patients.” #AntimicrobialResistance #AMR #GlobalHealth #SustainableFunding #PublicPrivatePartnerships #UNGAHLM GSK, BIOASTER, Helmholtz Centre for Infection Research, North Bristol NHS Trust, University of Liverpool, INSERM, Université de Poitiers, Erasmus MC, Medical University of Vienna, Fraunhofer-Gesellschaft, EFPIA - European Federation of Pharmaceutical Industries and Associations

Stay up-to-date on all of our latest news by subscribing to our Newsletter! At the end of every quarter, you'll receive a summary of key highlights in your inbox. Our Q3 edition is due out soon. Subscribe today 👉 https://lnkd.in/esqc72RW #PublicPrivatePartnerships #PioneeringMedicineTogether #Newsletter

🌍 Sustainable Funding: Key to Advancing Antimicrobial Resistance Research & Development 🦠 The threat of antimicrobial resistance (AMR) remains one of the most pressing challenges in global health. The GNA NOW Consortium, coordinated by Lygature and part of the AMR Accelerator, is leading the charge to develop novel Gram-negative antibacterials to tackle severe enteric infections caused by pathogens like Shigella, Campylobacter, E. coli, and Salmonella. But initiatives like GNA NOW and the AMR Accelerator can’t do it alone. They need sustained investment from governments, the private sector, and global stakeholders to ensure that R&D capacity remains strong and capable of delivering life-saving antibiotics. Public-private partnerships like GNA NOW and those under the Accelerator demonstrate that through collaboration, risk-sharing, and long-term commitment, it’s possible to bring new treatments to patients and strengthen the fight against AMR. 🔗 Find out more about the GNA NOW Consortium and the joint AMR Accelerator Call to Action ahead of the UN High-Level Meeting on AMR later this week 👉 https://lnkd.in/eSejxSDR GNA NOW is a #PublicPrivatePartnership funded by the Innovative Medicines Initiative, now Innovative Health Initiative (IHI). The Consortium consists of GSK (Scientific Lead), BIOASTER, Helmholtz Centre for Infection Research, North Bristol NHS Trust, University of Liverpool, INSERM, University of Poitiers, Erasmus MC, Medical University of Vienna, Fraunhofer-Gesellschaft, and Lygature (Coordinator). EFPIA - European Federation of Pharmaceutical Industries and Associations #AntimicrobialResistance #AMR #GlobalHealth #SustainableFunding #UNGAHLM #WeWontRest

It's been a productive couple of days in Porto for Lygature's GNA NOW Consortium. Yesterday, the Annual Consortium Meeting took place, bringing together partners to discuss the progress made over the past year and the key milestones and deliverables that lie ahead. Today, in collaboration with CARB-X, the Consortium organized a successful Expert Meeting to develop a Target Product Profile (TPP) for antibiotics targeting severe enteric infections in low- and middle-income countries (LMICs). The Expert Meeting engaged specialists in defining a TPP for antibiotics targeting bacterial enteric infections, specifically E. coli, Shigella, Salmonella, and Campylobacter, major health concerns in LMICs, particularly among young children. The session featured a panel discussion with Valeria Gigante (World Health Organization), Seamus O'Brien (Global Antibiotic R&D Partnership (GARDP)), Dorothy Yeboah-Manu (Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana), David Paterson (Saw Swee Hock School Of Public Health, Singapore), Sam Kariuki (Drugs for Neglected Diseases initiative - DNDi, Kenya), and Joseph (Herb) Harwell (Clinton Health Access Initiative, Inc.). Many thanks to our session chair, Erin Duffy of CARB-X. Lygature is proud to work with the following partners in GNA NOW: GSK, BIOASTER, Helmholtz Centre for Infection Research, North Bristol NHS Trust, University of Liverpool, INSERM, University of Poitiers, Erasmus MC, Medical University of Vienna, Fraunhofer-Gesellschaft. AMR Accelerator, Innovative Health Initiative (IHI). #PublicPrivatePartnership #CollectiveIntelligence #AMR ESCMID - European Society of Clinical Microbiology and Infectious Diseases 📷 (1) The Expert Meeting panelists and chair with Lygature colleagues Lianne Hulshof and Kristina Orrling, (2) Lygature's Kristina Orrling opening the Expert Meeting, (3) Members of the GNA NOW Consortium

Lygature's GNA NOW Consortium, in collaboration with CARB-X, is gearing up to host an expert meeting to develop a Target Product Profile (TPP) for antibiotics targeting severe enteric infections in low- and middle-income countries (LMICs). The meeting will take place on 17 September in Porto. It follows the Consortium's Annual Meeting on 16 September and precedes another prominent event in the #AMR space – the ESCMID - European Society of Clinical Microbiology and Infectious Diseases Conference, running from 17-20 September, also in Porto. The Expert Meeting will engage specialists in defining a TPP for antibiotics targeting bacterial enteric infections, specifically E. coli, Shigella, Salmonella, and Campylobacter, which are major health concerns in LMICs, particularly among young children. The two-hour session will feature a panel discussion with representatives from the World Health Organization, the Global Antibiotic R&D Partnership (GARDP), Drugs for Neglected Diseases initiative - DNDi, and the Clinton Health Access Initiative, Inc., to name just a few. Active audience participation will be encouraged, ensuring a comprehensive and inclusive approach to TPP development. All ESCMID registrants are free to join! Find out more 👉 https://lnkd.in/ezTjyJUR Erin Duffy, Kristina Orrling, Innovative Health Initiative (IHI), AMR Accelerator

📢Upcoming Masterclass: Unlocking the Potential of Data Sharing in Collaborative Projects The IHI recently released a new Data Sharing Playbook – a comprehensive guide designed to tackle the complex challenges of data sharing in large-scale multi-stakeholder projects. Lygature is proud to have been involved in the development of this important new resource, with our Senior Program Manager Jan-Willem Boiten contributing as a co-author. As Jan-Willem notes: “Data sharing in large projects is far more complex than it appears, often taking years before meaningful progress is made. This Playbook aims to change that by fostering collective learning and preventing the reinvention of the wheel.” To learn more and gain a deeper insight into the new Playbook, make sure not to miss the upcoming IHI Masterclass on 4 September. The online event, in which our colleague Jan-Willem will participate as part of the authoring team, will offer practical tips on unlocking the potential of data sharing in collaborative health projects. Find out more and access the link to register 👉 https://lnkd.in/e2UKD5Eu #DataSharing #HealthInnovation #Collaboration #Healthcare Innovative Health Initiative (IHI), EFPIA - European Federation of Pharmaceutical Industries and Associations, Teamit, EATRIS

📢 The European Platform for Neurodegenerative Diseases (EPND) has opened its first call for researchers interested to leverage biosamples and datasets to accelerate the discovery of diagnostic and therapeutic solutions. Lygature is a proud partner of EPND, which aims to accelerate the discovery of diagnostics and treatment for neurodegenerative diseases by removing barriers to data and biosample sharing and fostering collaboration. Submit your research proposal before 15 September, 2024